Ibex - About the company
Ibex is a series C company based in Tel Aviv (Israel), founded in 2016 by Chaim Linhart. It operates as a Provider of AI-powered diagnostic solutions for pathology. Ibex has raised $114M in funding from investors like 83NORTH, Kreos Capital and Octopus Ventures. The company has 89 active competitors, including 36 funded and 5 that have exited. Its top competitors include companies like Lunit, Aignostics and Onc.ai.
Company Details
Provider of AI-powered diagnostic solutions for pathology. The company has developed an analytical and diagnosis platform called the GALEN platform which assists with treatment diagnosis and planning. Other products such as First Read and Second Read use AI technology for the diagnosis of cancer based on pathological image analysis. The platform uses computer vision-based image analysis and machine learning technologies in digital pathology.
- Website
- ibex-ai.com
- Email ID
- *****@ibex-ai.com
Key Metrics
Founded Year
2016
Location
Tel Aviv, Israel
Stage
Series C
Total Funding
$114M in 4 rounds
Latest Funding Round
Ranked
2nd among 89 active competitors
Employee Count
94 as on Sep 30, 2026
Similar Companies
Sign up to download Ibex's company profile
Ibex's funding and investors
Ibex has raised a total funding of $114M over 4 rounds. Its first funding round was on Mar 26, 2019. Its latest funding round was a Series C round on Sep 06, 2023 for $*****. 6 investors participated in its latest round. Ibex has 8 institutional investors.
Here is the list of recent funding rounds of Ibex:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 06, 2023 | 8000949 | Series C | 6631966 | 3681456 | 8199114 | 9032247 |
Nov 09, 2022 | 6786309 | Series B | 2714595 | 4631824 | 9342631 | 6983885 |
Mar 09, 2021 | 1856478 | Series B | 2983742 | 8818643 |
View details of Ibex's funding rounds and investors
Ibex's founders and board of directors
Founder? Claim ProfileThe founders of Ibex is Chaim Linhart.
Here are the details of Ibex's key team members:
- Chaim Linhart: Co-Founder & CTO of Ibex. Contact Info: 1 email address
View details of Ibex's Founder profiles and Board Members
Ibex's employee count trend
Ibex has 94 employees as of Sep 26. Here is Ibex's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Ibex's Competitors and alternates
Top competitors of Ibex include Lunit, Aignostics and Onc.ai. Here is the list of Top 10 competitors of Ibex, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Lunit 2013, Seoul (South Korea), Public | Developer of medical software for cancer screening and oncology diagnostics | $135M | 71/100 | |
2nd | Provider of AI-powered diagnostic solutions for pathology | $114M | 68/100 | ||
3rd | Aignostics 2018, Berlin (Germany), Series B | Developer of artificial intelligence software for biomedical image analysis applications | $53.9M | 64/100 | |
4th | Onc.ai 2020, San Carlos (United States), Series A | AI-based cancer treatment and diagnosis platform for healthcare providers | $31M | 61/100 | |
5th | Valar Labs 2021, Palo Alto (United States), Series A | Developer of AI diagnostics for predicting cancer treatment response likelihood | $26.1M | 60/100 | |
6th | PAIGE 2018, New York City (United States), Acquired | Developer of AI applications and foundation models for cancer diagnostics | $241M | 59/100 | |
7th | Enspectra Health 2014, Mountain View (United States), Series A | Developer of medical devices for tissue imagining and cancer detection | $15.5M | 59/100 | |
8th | Proscia 2014, Philadelphia (United States), Series C | Provider of an AI and cloud-based digital pathology solution for cancer diagnosis | $129M | 59/100 | |
9th | Harbinger Health 2008, Cambridge (United States), Series B | AI-based cancer detection tool for providers | $290M | 57/100 | |
10th | Provider of AI-based pathological analysis platform | $18.3M | 57/100 |
Looking for more details on Ibex's competitors? Click here to see the top ones
Ibex's Investments and acquisitions
Ibex has made no investments or acquisitions yet.
Reports related to Ibex
Here is the latest report on Ibex's sector:
News related to Ibex
Media has covered Ibex for a total of 6 events in the last 1 year, 4 of them have been about company updates and 1 about partnerships.
•
Ibex Medical Analytics Establishes Biopharma Advisory Board to Advance AI-Powered Precision DiagnosticsBusiness Wire•May 05, 2026•Ibex
•
Ibex and HNL Lab Medicine partner for prostate cancer diagnosticsHospital Management•Mar 23, 2026•Hnl, Ibex, IBEX Global
•
•
•
•
Ibex Medical Analytics Announces IVDR Certification for HER2 SolutionBusiness Wire•Sep 04, 2025•Ibex
•
•
Philips and Ibex expand partnership to enhance AI-enabled AccessibilityGlobeNewswire•Mar 24, 2025•Philips, Ibex
•
Glimpse Closes $10M Series A FinancingFinSMEs•Mar 06, 2025•The Glimpse Group, TDK Ventures, Ibex, Flybridge Capital Partners
•
Are you a Founder ?
FAQs about Ibex
Explore our recently published companies
- Pack Hacker - 2017 founded, Unfunded company
- Barrierefrei - Austria based, Unfunded company
- Ma:Nyo - Unfunded company
- Clipping Path America - Unfunded company
- Elevate in Maine - Unfunded company
- Zodiac Thump Designs - 2010 founded, Unfunded company
